# Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

> **NCT03126578** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 32 (actual)

## Conditions studied

- Drug Interaction Potentiation

## Interventions

- **DRUG:** LEO 32731
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT03126578
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-31
- **Primary completion:** 2017-10-20
- **Final completion:** 2017-10-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126578, "Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03126578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*